Egunsola, Oluwaseun and Adefurin, Abiodun and Fakis, Apostolos and Jacqz-Aigrain, Evelyne and Choonara, Imti and Sammons, Helen (2013) Safety of fluconazole in paediatrics: a systematic review. European Journal of Clinical Pharmacology, 69 (6). pp. 1211-1221. ISSN 0031-6970

Access from the University of Nottingham repository:
http://eprints.nottingham.ac.uk/2655/1/Egunsola_Safety_of_flucanozole.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the Creative Commons Attribution Non-commercial licence and may be reused according to the conditions of the licence. For more details see: http://creativecommons.org/licenses/by-nc/2.5/

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk
Safety of fluconazole in paediatrics: a systematic review

Oluwaseun Egunsola · Abiodun Adefurin · Apostolos Fakis · Evelyne Jacqz-Aigrain · Imti Choonara · Helen Sammons

Received: 9 July 2012 / Accepted: 27 November 2012 / Published online: 17 January 2013 © The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract

Purpose To determine the safety of fluconazole in neonates and other paediatric age groups by identifying adverse events (AEs) and drug interactions associated with treatment.

Methods A search of EMBASE (1950–January 2012), MEDLINE (1946–January 2012), the Cochrane database for systematic reviews and the Cumulative Index to Nursing and Allied Health Literature (1982–2012) for any clinical study about fluconazole use that involved at least one paediatric patient (≤17 years) was performed. Only articles with sufficient quality of safety reporting after patients’ exposure to fluconazole were included.

Results We identified 90 articles, reporting on 4,209 patients, which met our inclusion criteria. In total, 794 AEs from 35 studies were recorded, with hepatotoxicity accounting for 378 (47.6 %) of all AEs. When fluconazole was compared with placebo and other antifungals, the relative risk (RR) of hepatotoxicity was not statistically different [RR 1.36, 95 % confidence interval (CI) 0.87–2.14, \( P=0.175 \) and RR 1.43, 95 % CI 0.67–3.03, \( P=0.352 \), respectively]. Complete resolution of hepatotoxicity was achieved by 84 % of patients with follow-up available. There was no statistical difference in the risk of gastrointestinal events of fluconazole compared with placebo and other antifungals (RR 0.81, 95 % CI 0.12–5.60, \( P=0.831 \) and RR 1.23, 95 % CI 0.87–1.71, \( P=0.235 \), respectively). There were 41 drug withdrawals, 17 (42 %) of which were due to elevated liver enzymes. Five reports of drug interactions occurred in children.

Conclusion Fluconazole is relatively safe for paediatric patients. Hepatotoxicity and gastrointestinal toxicity are the most common adverse events. It is important to be aware that drug interactions with fluconazole can result in significant toxicity.

Keywords Fluconazole · Safety · Neonates · Paediatrics · Hepatotoxicity

Background

Invasive candidiasis is associated with high morbidity and mortality in neonates and children, with the highest incidence in premature neonates. Studies in neonates have shown an incidence rate of 2–28 % depending on birth weight [1]. Amphotericin B is the drug of choice for the treatment of invasive candidiasis; however, nephrotoxicity has been associated with this drug [2]. Fluconazole remains a suitable alternative and has also been used routinely as prophylaxis for very low birth weight neonates and children with other risk factors. Risk factors in neonates include prematurity, broad spectrum antibiotics, central venous catheter, mechanical ventilation, use of H2 receptor antagonists and parenteral nutrition. Immunosuppression from endogenous or exogenous causes, such as cystic fibrosis, malignancy, drug therapy (cytotoxics, corticosteroids, immunosuppressives),
haematological diseases, organ or bone marrow transplantation and prolonged intensive care, are factors in paediatric patients beyond the neonatal period [3, 4].

Fluconazole, a bis-triazole broad spectrum antifungal agent discovered by Richardson et al. during a programme initiated by Pfizer Central Research in 1978 [5], is a suitable alternative to amphotericin B. It is available as an oral tablet, oral suspension and intravenous formulation. Its antifungal activity is achieved by preventing fungal membrane sterol synthesis through the inhibition of cytochrome P450 (CYP)-dependent lanosterol C-14α-demethylase conversion of lanosterol to ergosterol, resulting in an impairment of fungal cell replication. Although CYP is also present in mammalian cells, fluconazole is highly selective for fungal CYP [6, 7].

Fluconazole is well absorbed orally with extensive bioavailability, and most of the drug is excreted unchanged in the urine; only 11 % is excreted as metabolites, while a small percentage is excreted in the faeces. The elimination half-life of the drug is about 30 h (range 20–50 h), with a faster rate of elimination in older children than adults. In neonates, however, the mean plasma elimination half-life is longer (55–90 h) [8–10].

Fluconazole is licensed in children for mucosal candidiasis, invasive candidiasis and prophylaxis against candidal infections in immunocompromised patients. Common adverse reactions ascribed to the drug from clinical trials include deranged liver enzymes, cholestasis, headache, skin rash and gastrointestinal symptoms [11].

Due to the increasing use of the drug as prophylaxis and for the treatment of fungal infections in paediatric and neonatal patients, as well the need to identify toxicity associated with treatment, we decided to undertake a systematic review of safety data published on fluconazole in these populations.

Method

Search strategy

We searched MEDLINE (1946–January 2012), EMBASE (1950–January 2012), the Cochrane database for systematic reviews, Cumulative Index to Nursing and Allied Health Literature (CINAHL1982–January 2012) and the Cochrane library (Cochrane Central Register of Controlled Trials, Cochrane database of systematic reviews, and Database of abstracts of reviews of effects) for any clinical study about fluconazole use that involved at least one paediatric patient (≤17 years). Any study with involvement of a paediatric age group participant taking at least a single dose of fluconazole was eligible. Only studies with a report of safety after exposure to fluconazole in the paediatric patients were included. There was no restriction on the language of publication of the articles as translations to extract relevant data were done; where translations were not possible, abstracts containing relevant data were used. Also included in this review were any clinical study, whether comparative or non-comparative, randomised controlled trials (RCTs) or case reports and also letters to the editors that documented exposure of a paediatric patient to fluconazole and reported on safety. Included articles and extracted data were validated by two reviewers. Search terms comprised free text words and subject headings. These included terms relating to azole or imidazole or fluconazole, adverse effects or adverse drug reactions or side effects, pharmacokinetics and drug interactions.

Data extraction

Data extracted from each study included the year of publication, type of study, number of paediatric patients exposed, age of paediatric patients exposed, doses of fluconazole used, route of administration and safety data. The safety data extracted were occurrence of any adverse event (AE), any drug interactions, any withdrawal due to AEs and any drug-related death.

Data quality assessment

To minimise the risk of bias, we assessed the quality of included RCTs using the CONSORT checklist for reporting of harm [12]. All RCTs with scores of ≥6 out of nine criteria were considered to provide good quality safety reporting. Cohort studies were scored using the STROBE checklist [13], where a score of >70 % is considered to be good. Case series were evaluated using the health technology assessment checklist [14], and all studies fulfilling the good or satisfactory criteria were included.

Data collection

The relevant data were extracted onto the data extraction form. Participants in the study were grouped into paediatric age groups of preterm neonates (<36 weeks gestation, 0–27 days), full-term neonates (0–27 days, >37 weeks gestation), infants and toddlers (28 days–23 months), children (2–11 years) and adolescents (12–17 years). All reported AEs were pooled together from the various studies. The duration of treatment was grouped into <21, 21–42 and >42 days; the treatment dose was grouped into <3, 3–6 and >6 mg/kg; the route of administration was recorded as intravenous (IV), oral or IV and oral.

Statistical analysis

Meta-analysis was performed using the Stata/IC v.11 statistical package (StataCorp LP, College Station, TX). Only
those studies rated as good were included in the meta-analysis. Studies with zero frequency were included in the meta-analysis by entering 0.5 to zero cells so that all of the information could be used.

The relative risk (RR) was calculated for these binary outcomes (RR > 1 indicates a positive effect of fluconazole). We calculated the pooled relative risks with fixed effect models using the Mantel and Haenszel method. The heterogeneity of the model was examined by calculating the DerSimonian and Laird’s Q statistic [15] and the I2-statistic [16]. Both were compared with a chi-square distribution with degrees of freedom (df) equal to the number of trials minus one. We used the Q statistic for testing the presence of heterogeneity and the I2-statistic for estimating the degree of heterogeneity. When heterogeneity was observed, we used the with random effect models as suggested by DerSimonian and Laird [15].

The forest plots have been created for presenting the pooled effects of fluconazole. The effects of indication, age groups, dose range, route of administration and duration of treatment on risk of AEs in the fluconazole groups against the active comparator were assessed using random effect models.

Poisson regression analysis was used to test the effect of indication, age groups, dose groups, route of administration and duration of treatment on incidence of AEs and hepatotoxicity in the fluconazole group. The incidence–rate ratios (IRR) are reported from the Poisson regression analysis. All results are reported with 95 % confidence intervals (CIs), and all P values are two-tailed.

Results

Our search revealed 1,702 articles, of which 117 met our inclusion criteria (Fig. 1). These were reduced to 90 following assessment of data quality. Two articles in foreign languages (Chinese and Hebrew) were excluded because the articles could not be translated. All 90 articles were published between 1986 and 2011, and the most frequent type of studies was the case report, followed by the case series and the RCT (Table 1). Thirty-one (34 %) of the studies involved neonates only.

The largest group of patients who received fluconazole were taking part in RCTs (1,793 patients). These studies compared fluconazole with griseofulvin, placebo, nystatin, amphotericin B and other azole antifungals. One study compared different routes of administration [17]. Seven of the 14 RCTs were exclusively conducted in neonates (term and preterm) [17–23], while the remainder involved children across the paediatric age spectrum (birth–17 years) [24–31]. Fluconazole was used as prophylaxis in six of the eight neonatal RCTs.

The second largest group of patients on fluconazole (1,564) were enrolled in cohort studies [32–38]. All cohort study patients were preterm neonates, with fluconazole administered either prophylactically orally or intravenously. The other large group of patients (795) were in case series [39–59]. Fifteen of these studies were conducted in term and preterm neonates, while the others cut across the paediatric age group. Seventy-seven patients were involved in eight pharmacokinetic studies [60–67], three of which were performed exclusively in preterm and term neonates.

Dosage and administration

Fluconazole was either administered as prophylaxis or therapeutically. The median prophylactic dose was 3 mg/kg/day [interquartile range (IQR) 3–6 mg/kg/day] over a median period of 42 days (IQR 1.57–42 days). The median administered therapeutic dose was 6 mg/kg/day (IQR 5–6 mg/kg/day) over a median duration of 42 days (IQR 14–67 days). Therapeutic indications were invasive candidiasis, tinea capitis, fungal meningitis, urinary tract infection and other mycotic infections. The duration of treatment ranged between 1 day [40–42] and 9 years [68]. The most common routes of administration were oral (30 %), IV (23 %) or both (28 %) (Table 1).

Toxicity

A total of 4,209 patients from 90 studies were exposed to fluconazole, with 794 AEs recorded in 35 studies. Hepatotoxicity was the most common AE across all age groups. About one-third of the reviewed articles exclusively involved preterm and term neonates, accounting for 2,434 fluconazole exposed neonates. A total of 307 AEs (38.6 %) were recorded in neonates, of which 295 (96.1 %) were hepatotoxic effects. Gastrointestinal events were the second most common AE documented. One hundred cases of respiratory symptoms were recorded in one study, none of which was found to be drug-related. Other adverse events identified were renal dysfunction, haematological abnormalities and rash (Table 2). The relative risk of all AEs in the fluconazole group was not statistically different from those treated with placebo (RR 1.30, 95 % CI 0.84–2.03, P=0.238). Compared to all other antifungal drugs there was again no significant increase in the risk (RR 1.05, 95 % CI 0.62–1.80, P=0.85) (Fig. 2a). The overall relative risk of adverse events in the fluconazole group was not significantly different within the treatment group (RR 0.82, 95 % CI 0.49–1.36, P=0.437) or the prophylaxis group (RR 1.68, 95 % CI 0.55–5.11, P=0.364) compared to other antifungal drugs. There were 378 recorded cases of hepatotoxicity, accounting for just under half of all the AEs across all age groups. The majority
of cases (295) occurred in neonates. The relative risk of hepatotoxicity with fluconazole was 1.36 (95 % CI 0.87–2.14) and 1.43 (95 % CI 0.67–3.03) when compared with placebo and other antifungals, respectively (Fig. 2a and 2b); these relationships were not statistically significant ($P=0.175$ and 0.352, respectively). However, when compared against nystatin, the only comparator to have sufficient numbers of patients for analysis, there was a significant increase in risk of hepatotoxicity with fluconazole (RR 1.92, 95 % CI 1.13–3.26, $P=0.016$) (Fig. 2c).

Poisson regression analysis of the effect of treatment, age group, dose, route of administration, indication and duration of treatment on the incidence of hepatotoxicity of fluconazole was performed. This showed that the incidence of hepatotoxicity with therapeutic fluconazole was significantly greater than that with prophylaxis (IRR 5.34 95 % CI 1.99–14.37, $P=0.001$), while the duration of treatment had no effect. Although the incidence of hepatotoxicity in neonates on fluconazole was greater than that in children (IRR 1.33, 95 % CI 0.63–2.80), this effect was not statistically significant ($P=0.451$). The incidence of hepatotoxicity appears to decrease with increasing dose (IRR 0.52, 95 % CI 0.37–0.74, $P=0.001$). Patients on oral fluconazole were less likely to have hepatotoxicity than those on IV fluconazole (IRR 0.21, 95 % CI 0.92–0.47, $P=0.001$).

Only three of the cohort studies reported any AE; one of which was a prophylactic study which recorded 127 cases of cholestasis in 409 fluconazole-exposed extremely low birth weight neonates. However, this study did not report the number of non-exposed neonates. Of these patients, 69 % recovered, while the others were discharged or transferred to other facilities [36]. Another prophylactic cohort study recorded 60 cases of cholestasis in 140 fluconazole-exposed extremely low birth weight neonates as against 12 in 137 non-exposed neonates ($P<0.001$) [34].

Of all the 378 hepatotoxicity cases, resolution of symptoms was not determined in 113 (30 %) cases, while in 42 (11 %) cases, all involving neonates, there was no improvement at discharge or upon referral to another hospital (188 neonates and 35 children had completely recovered during treatment or shortly after). Therefore, 84 % of patients, for whom follow-up was complete, had resolution of symptoms. Hepatotoxicity was the most frequent reason for withdrawal of the drug. Of the 41 drug-related withdrawals, 17 (42 %) were due to elevated liver enzymes [26, 27, 30, 36, 42, 66, 69].

Gastrointestinal (GI) symptoms including nausea, vomiting, abdominal pain, diarrhea, dyspepsia, anorexia and gastritis accounted for 15.4 % of AEs (122 cases) (Table 2). There was only one recorded case of GI event in neonates.
There was no statistical difference in the risk of GI events of fluconazole compared with placebo (RR 0.81, 95% CI 0.12–5.60, P=0.831). The risk of GI events increased, but not significantly, when fluconazole was compared with other comparator antifungal drugs (RR 1.23, 95% CI 0.88–1.71, P=0.235) and nystatin (RR 2.02, 95% CI 0.66–6.23, P=0.219). Poisson regression analysis showed that the incidence of GI AEs were lower in neonates than children (IRR 0.15, 95% CI 0.03–0.66, p=0.012), while dose (IRR 1.07, 95% CI 0.88–1.71, P=0.235) and duration of treatment (IRR 1.01, 95% CI 0.99–1.03, P=0.07) were unlikely to significantly affect the incidence of GI events. Although oral administration increased the incidence of GI AEs, this increase was not significant (IRR 3.22, 95% CI 0.72–14.33, P=0.125).

There was a decrease in mortality when fluconazole was compared with placebo, but this was not significant (RR 0.62, 95% CI, 0.38–1.03, P=0.067). The mortality rate between the fluconazole group and antifungal drugs was not different (RR 1.01, 95% CI 0.72–1.41, P=0.960) (Table 3). No cases of drug-related death were documented.

There were ten reported cases of serious AEs, five of which were not treatment-related [30]. The other serious AEs were five drug interactions [70–74]. Two interactions in children were with all-trans retinoic acid (ALTRA) and resulted in acute renal failure and pseudotumour cerebri [70, 71]. Another case of acute renal failure in a 9-year-old child was recorded following interaction with tacrolimus [73]. A 12-year-old child had syncope following co-administration

Table 1 Summary of the 90 studies that reported on the safety of fluconazole in paediatric populations included in this review

| Characteristics of studies | Number of studies | Number of patients |
|----------------------------|------------------|-------------------|
| Type of study              | n=90             | n=4,209           |
| Case series                | 23               | 795               |
| Case reports               | 38               | 65                |
| RCT                        | 14               | 1,793             |
| Cohort studies             | 7                | 1,564             |
| Pharmacokinetics studies   | 8                | 77                |
| Route of Administration    | n=90             | n=4,209           |
| Oral                      | 27               | 1,465             |
| Intravenous and oral       | 26               | 1,602             |
| Intravenous               | 21               | 971               |
| Not reported              | 13               | 170               |
| Intraperitoneal/rectal     | 3                | 15                |
| Age groups                 | n=90             | n=4,209           |
| Preterm neonates           | 20               | 2,354             |
| Term neonates             | 7                | 43                |
| Term and preterm neonates | 4                | 37                |
| Other paediatric age groupsa | 59             | 1,775             |

RCT, Randomised controlled trial

a Including studies involving infants up to adolescence (some of which included some neonates) and paediatric studies for which the age group was not stated

Table 2 Reported adverse events from 35 studies

| Adverse events          | Preterm neonates only | Term and preterm neonates | Infancy–adolescence | Othersa | Total |
|-------------------------|-----------------------|---------------------------|---------------------|---------|-------|
| Conjugated bilirubin    | 231                   | 4                         | 1                   | –       | 236   |
| ↑Liver enzymes          | 55                    | 13                        | 47                  | 16      | 131   |
| Respiratory infectionb  | –                     | –                         | 100                 | –       | 100   |
| GIT symptomsc           | –                     | –                         | 55                  | –       | 55    |
| Headache                | –                     | –                         | 24                  | –       | 24    |
| Vomiting                | –                     | 1                         | 20                  | 1       | 22    |
| Abdominal pain          | –                     | –                         | 18                  | –       | 18    |
| Other skin conditions   | –                     | –                         | 21                  | –       | 21    |
| Rash/urticarial         | –                     | –                         | 19                  | –       | 19    |
| Diarrhoea               | –                     | –                         | 16                  | 1       | 17    |
| Nausea                  | –                     | –                         | 10                  | –       | 10    |
| Eosinophilia            | –                     | 6                         | 1                   | 1       | 8     |
| Altered renal function  | –                     | 3                         | 4                   | –       | 7     |
| Electrolyte derangement | 2                     | –                         | –                   | –       | 2     |
| Pruritus                | –                     | –                         | 6                   | –       | 6     |
| Thrombocytopenia        | 5                     | –                         | –                   | –       | 5     |
| Anaemia                 | –                     | 2                         | –                   | –       | 2     |
| Others                  | –                     | –                         | 109                 | 2       | 111   |
| Total                   | 293                   | 29                        | 451                 | 21      | 794   |

GIT, Gastrointestinal tract

a Number of adverse events (AEs) cut across age categories
b Obtained from a single study
c Patients with anorexia, gastritis, dyspepsia, GI upset or a combination of any of nausea, vomiting, diarrhoea and abdominal pain

There was no statistical difference in the risk of GI events of fluconazole compared with placebo (RR 0.81, 95% CI 0.12–5.60, P=0.831). The risk of GI events increased, but not significantly, when fluconazole was compared with other comparator antifungal drugs (RR 1.23, 95% CI 0.88–1.71, P=0.235) and nystatin (RR 2.02, 95% CI 0.66–6.23, P=0.219). Poisson regression analysis showed that the incidence of GI AEs were lower in neonates than children (IRR 0.15, 95% CI 0.03–0.66, p=0.012), while dose (IRR 1.07, 95% CI 0.85–1.39, P=0.585) and duration of treatment (IRR 1.01, 95% CI 0.99–1.03, P=0.07) were unlikely to significantly affect the incidence of GI events. Although oral administration increased the incidence of GI AEs, this increase was not significant (IRR 3.22, 95% CI 0.72–14.33, P=0.125).

There was a decrease in mortality when fluconazole was compared with placebo, but this was not significant (RR 0.62, 95% CI, 0.38–1.03, P=0.067). The mortality rate between the fluconazole group and antifungal drugs was not different (RR 1.01, 95% CI 0.72–1.41, P=0.960) (Table 3). No cases of drug-related death were documented. There were ten reported cases of serious AEs, five of which were not treatment-related [30]. The other serious AEs were five drug interactions [70–74]. Two interactions in children were with all-trans retinoic acid (ALTRA) and resulted in acute renal failure and pseudotumour cerebri [70, 71]. Another case of acute renal failure in a 9-year-old child was recorded following interaction with tacrolimus [73]. A 12-year-old child had syncope following co-administration
with amitriptyline [72]. Co-administration of fluconazole with vincristine also caused severe constipation [74].

### Discussion

Hepatotoxicity was the most frequent AE described in this systematic review of the safety of fluconazole. It usually manifested as conjugated hyperbilirubinaemia or deranged liver enzymes and was also the most frequent reason for withdrawal of fluconazole in both neonates and paediatric patients. Our review demonstrated that over 80 % of the cases with known outcomes had complete resolution during treatment or after completion of therapy. Hepatotoxicity risk was significantly greater in patients on fluconazole compared with nystatin ($p=0.016$). The better safety of nystatin compared with fluconazole has also been described by previous authors [75]. There was an increased risk of hepatotoxicity with fluconazole than placebo, but this increase was not significant ($p=0.175$). Prematurity, total parenteral nutrition, infection and congenital abnormalities are known risk factors for hepatotoxicity in neonates [76]. More neonates than

---

### Figure 2

#### a
Fluconazole adverse effects (AEs) compared to those of other antifungals.

#### b
Fluconazole hepatotoxicity compared with that of placebo.

#### c
Fluconazole hepatotoxicity compared with that of nystatin.

| Study                      | RR (95% CI) | Fluconazole | Comparator | Weight |
|----------------------------|-------------|-------------|------------|--------|
| Aydemir et al 2012         | 1.01 (0.02, 50.41) | 5/93.5      | 5/94.5     | 1.72   |
| Driessen et al 1996        | 0.39 (0.13, 1.15)  | 3/12        | 7/11       | 11.81  |
| Flynn et al 1994           | 1.77 (0.83, 3.76)  | 17/94       | 9/88       | 15.67  |
| Foster et al 2002          | 0.91 (0.79, 1.06)  | 323/771     | 134/292    | 22.41  |
| Groll et al 1997           | 4.50 (1.77, 11.41) | 18/25       | 4/25       | 13.46  |
| Gupta et al 2001           | 0.25 (0.01, 4.35)  | 5/55.5      | 6/150      | 3.00   |
| Hernandez-Sampelayo et al 94 | 0.23 (0.03, 1.90) | 1/24        | 4/22       | 4.98   |
| Mondal et al 2004          | 0.48 (0.05, 4.88)  | 1/22        | 2/21       | 4.27   |
| Ninane et al 1994          | 1.82 (1.16, 2.85)  | 45/245      | 26/257     | 19.62  |
| Violais et al 2009         | 0.08 (0.00, 1.33)  | 5/38.5      | 7/42       | 3.06   |
| Overall (I-squared = 69.8%, $p = 0.000$) | 1.05 (0.62, 1.80) | 409.5/1375.5 | 199.5/1002.5 | 100.00 |

| Study                      | RR (95% CI) | Fluconazole | Placebo   | Weight |
|----------------------------|-------------|-------------|-----------|--------|
| Aydemir et al 2012         | 0.98 (0.02, 48.80) | 5/93.5      | 5/91.5    | 1.76   |
| Kaufman et al 2001         | 1.00 (0.21, 4.72)  | 3/50        | 3/50      | 10.44  |
| Kaufmann et al 2011        | 2.61 (0.28, 24.09) | 3/46        | 1/40      | 3.72   |
| Manzoni et al 2007         | 1.36 (0.84, 2.22)  | 50/216      | 18/106    | 84.07  |
| Overall (I-squared = 0.0%, $p = 0.917$) | 1.36 (0.87, 2.14) | 56.5/405.5  | 22.5/287.5 | 100.00 |
children developed hepatotoxicity, even though this incidence was not significantly different. Although animal studies have demonstrated a dose-dependent histological evidence of hepatotoxicity [77], this review did not show any significant effect of increasing dose on liver toxicity, probably because most of the reviewed articles administered fluconazole within the therapeutic dose limit of ≤12 mg/kg.

Our review also showed that GI events were the second most common AE after hepatotoxicity; however, the relative risk of this event is not statistically different between patients on fluconazole and placebo or other antifungals. There was just one recorded case of a GI AE in neonates. This may be related to the fact that neonates are unable to self-report these events, and GI events are less likely to be identified by clinicians and parents. Nausea and abdominal pain, for example, are extremely difficult, if not impossible to detect in this age group.

Drug interactions with fluconazole have been documented. Fluconazole is a potent inhibitor of CYP enzymes and is known to inhibit both CYP3A and CYP1A2 enzymes [78]. Therefore, drug interactions with medicines such as tacrolimus, vincristine, ALTRA, midazolam, caffeine and amitriptyline are likely. Clinicians need to be aware of these interactions and monitor for AEs.

The relatively small number of patients in several of the groups for meta-analysis requires that these results be interpreted with caution. There were very few placebo controlled RCTs—a pool of which involved fewer than 500 patients. Such a small number may be insufficient to detect rare events. Additionally, the majority of the RCTs are primarily efficacy studies with poor and inconsistent reporting of safety outcomes. We excluded about 25 % of the identified RCTs because of their poor quality of safety reporting. Some of these limitations were also identified in several studies evaluating the quality of safety reporting in RCTs [79, 80]. Authors often fail to indicate the severity of the AEs and, in several cases, the relationship with medication was not determined. In addition, the duration of observation and outcome of AEs were often not established, with about 30 % of cases of hepatotoxicity not followed up to identify whether resolution had occurred. Comparison of fluconazole with other

Table 3 Effect of fluconazole compared with placebo, nystatin and active comparator

|                          | Relative risk | 95 % confidence interval | P value |
|--------------------------|---------------|--------------------------|---------|
| Placebo                  |               |                          |         |
| Hepatotoxicity           | 1.37          | 0.87–2.14                | 0.175   |
| GI events                | 0.81          | 0.12–5.59                | 0.831   |
| Mortality                | 0.62          | 0.37–1.03                | 0.067   |
| Withdrawal due to AE     | 0.78          | 0.08–7.24                | 0.828   |
| Other antifungals        |               |                          |         |
| Hepatotoxicity           | 1.43          | 0.67–3.03                | 0.352   |
| GI events                | 1.23          | 0.88–1.71                | 0.235   |
| Mortality                | 1.01          | 0.72–1.41                | 0.960   |
| Withdrawal due to AE     | 1.25          | 0.62–2.53                | 0.534   |
| Nystatin                 |               |                          |         |
| Hepatotoxicity           | 1.92          | 1.13–3.26                | 0.016*  |
| GI events                | 2.02          | 0.66–6.23                | 0.219   |
| Mortality                | 1.01          | 0.02–50.41               | 0.825   |
| Withdrawal due to AE     | 1.01          | 1.11–9.59                | 0.992   |

* (<0.05) statistically significant
antifungal agents, except nystatin, was also impossible because of the paucity of good quality studies. Further research should include studies with extended follow-up to capture data regarding the resolution of hepatotoxicity, especially in the neonatal population.

In conclusion, fluconazole is relatively safe for paediatric patients. Hepatotoxicity and GI events are the most common AEs. It is important to be aware that drug interactions with fluconazole can result in significant toxicity [81–111].

Acknowledgements This work is part of the TINN network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme (grant agreement no. 223614).

Funding This research was conducted within the framework of a TINN project, a FP7 project sponsored by the European Commission.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Benjamin DK Jr, Stoll BJ, Gantz MG, Walsh MC, Sanchez PJ, Das A et al (2010) Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 126:e865–e873
2. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE Jr et al (2009) Clinical practice guidelines for the management of candidiasis: update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535
3. Rolildes E (2011) Invasive candidiasis in neonates and children. Early Hum Dev 87[Suppl 1]:S57–S76
4. Festekjian A, Neely M (2011) Incidence and predictors of invasive candidiasis associated with candidaemia in children. Mycoses 54:146–153
5. Richardson K, Cooper K, Marriot MS, Tarbit MH, Troke PF, Whittle PJ (1999) Discovery of fluconazole: a novel antifungal agent. Rev Infect Dis 12:S267–S271
6. Grant SM, Clissold SP (1990) Fluconazole: a review of its pharmacodynamics and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 39:877–916
7. Kelly SL, Lamb DC, Kelle DE (1999) Y132H substitution in Candida albicans sterol 14a-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett 180:171–175
8. Pfizer Inc (2011) DIFLUCAN®. Available from http://labeling.pfizer.com. Accessed: 7 April 2012
9. Brammer KW, Coates PE (1994) Pharmacokinetics of fluconazole in paediatric patients. Eur J Clin Microbiol Infect Dis 13:325–329
10. Saxon H, Hoppu K, Pohjavanainen M (1993) Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 54:269–277
11. Medicines and Healthcare products Regulatory Agency (MHRA) 2005. Fluconazole 2 mg/ml solution for infusion. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websitesresources/con079044.pdf. Accessed: 7 Dec 2011
12. de Vries TW, van Roon EN (2010) Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. Arch Dis Child 95:1023–1026
13. Potts JA, Rothman AL (2008) Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations. Trop Med Int Health 13(11):1328–1340
14. Maund E, Craig D, Suekarran S, Neilson AR, Wright K, Brealey S, Dennis L, Goodchild L, Hanchard N, Rangan A, Richardson G, Robertson J, McDaid C (2012) Management of frozen shoulder: a systematic review and cost-effectiveness analysis. Health Technol Assess 16(11):419
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327:557–560
17. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB (2001) Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 107:293–298
18. Violaris K, Carbone T, Bateman D, Olawepo O, Doraismwamy B, Lacorte M (2010) Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants. Am J Perinatol 27:73–78
19. Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D et al (1996) Fluconazole vs. amphotericin B for the treatment of neonatal fungal sepsisemia: A prospective randomized trial. Pediatr Infect Dis J 15:1107–1112
20. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG (2001) Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2345:1660–1666
21. Manzoni P, Stolfi I, Pugni L, Decembrino L, Magnani C, Vettrano G et al (2007) A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 356:2483–2495
22. Aydemir C, Oguz SS, Dizdar EA, Akar M, Sarikabaday Yu, Sibel S et al (2011) Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonization and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 96:F164–F168
23. Kaufman DA, Cuff AL, Wamstad JB, Boyle R, Gurka MJ, Grossman LB et al (2011) Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 158:759–65.e1
24. Groll AH, Just-Nuebling G, Kurz M, Mueller C, Nowak-Goettel U, Schwabe D et al (1997) Fluconazole versus nystatin in the prevention of Candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 40:855–862
25. Gupta AK, Adam P, Dlova N, Lynde CW, Hofstader S, Morar N et al (2001) Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol 18:433–438
26. Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, Peters VB, Pitel PA et al (1995) Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. J Pediatr 127:322–328
27. Ninane J, Gluckman E, Gibson BS, Stevens RF, Darbyshire PJ, Ball LM et al (1994) A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur J Clin Microbiol Infect Dis 13:330–337
28. Schaison GS, Decroly FC (1991) Propylaxis, cost and effectiveness of therapy of infections caused by Gram-positive organisms in neutropenic children. J Antimicrob Chemother 27[Suppl B]:61–67
29. Hernandez-Sampelayo T, Roberts A, Tricoire J, Gibb DM, Holzel H, Novelli VM et al (1994) Fluconazole versus ketoconazole in
the treatment of oropharyngeal candidiasis in HIV-infected children. ECIMD 13:340–344
30. Foster KW, Friedlander SF, Panzer H, Ghannoum MA, Elewski BE (2005) A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. J Am Acad Dermatol 53:798–809
31. Mondal RK, Singh SC, Chakrabarti A, Jayashree M (2004) Randomized comparison between fluconazole anditraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med 5:561–565
32. Bertini G, Perugi S, Dani C, Filippi L, Pratesi S, Rubaltelli FF (2005) Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 147:162–165
33. Manzoni P, Arisio R, Mostert M, Leonessa M, Farina D, Latino MA et al (2006) Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics 117(1):e22–e32
34. Aghai ZH, Mudmuluru M, Nakha TA, Amendolia B, Longo D, Kemble N et al (2006) Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 26:550–555
35. Weitkamp JH, Ozdas A, LaFleur B, Potts AL (2008) Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol 28:405–411
36. Healy CM, Campbell JR, Zaccaria E, Baker CJ (2008) Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatr Infect Dis J 27:731–740
37. Uko S, Sogher LM, Vega M, Marsh J, Reinersman GT, Herring L et al (2006) Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 117:1243–1252
38. Manzoni P, Leonessa M, Galletto P, Latino MA, Arisio R, Maule M et al (2008) Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subtypes. Pediatr Infect Dis J 27:731–737
39. Gupta AK, Dlova N, Taborda P, Morar N, Taborda V, Lynde CW et al (2000) Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol 142:965–968
40. Huttova M, Hartmanova I, Kralinsky K, Filka J, Uher J, Kurak J (1997) Experience of fluconazole granules and injection in pediatric patients. Jpn J Antibiot 47:280–288
41. Sugita K, Miyake M, Takitani K, Murata T, Nishimura T, Aoki S (1994) Pharmacokinetic and clinical evaluations of fluconazole in pediatric patients. Jpn J Antibiot 47:296–303
42. Groll A, Nowak-Gottl U, Wildfeuer A, Weise M, Schwabe D, Gerein V et al (1994) Fluconazole prophylaxis of oropharyngeal candidiasis in pediatric cancer patients with severe mucositis following antineoplastic chemotherapy. Mycoses 35(Suppl):35–40
43. Godula-Stügluk U (1997) Endotracheal colonisation with Candida albicans in prolonged ventilated neonates—clinical manifestations and treatment with oral fluconazole. Pediatr Relat Top 35:459–465
44. Caballero S, Jaraba Caballero MP, Fernández Gutiérrez F, Muriel Zafra I, Huertas Muñoz MD, Álvarez Marcos R et al (1998) Prospective study of Candida sepsis in the neonate. Estudio prospectivo de sepsis por Candida en el recien nacido 48:639–643
45. Saporito N, Tina LG, Betta P, Sciaccia A (1994) Fluconazole in the treatment of Candida albicans infection in premature infants. Clin Pediatr Chir 16:263–267
46. Byers M, Chapman S, Feldman S, Parent A (1992) Fluconazole pharmacokinetics in the cerebrospinal fluid of a child with Candida tropicalis meningitis. Pediatr Infect Dis J 11:895–896
47. Krzeska L, Yeates RA, Pfaff G (1993) Single dose intravenous fluconazole prophylaxis in children. J Perinatol 13:631–637
48. Fasano C, O’Keeffe J, Gibbs D (1994) Fluconazole treatment of children with severe fungal. Eur J Clin Infect Dis 13:344–347
49. Wainer S, Cooper PA, Gouws H, Akierman A (1997) Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 16:763–767
50. Viscosi C, Castagnola E, Fioredda F, Ciravegna B, Barigione G, Terragna A (1991) Fluconazole in the treatment of Candida albicans in immunocompromised children. Antimicrob Agents Chemother 35:365–367
51. Cap J, Mojszeova A, Kaysereva E, Babenska E, Hatiar K, Trupl J et al (1993) Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer. Chemotherapy 39:438–442
52. Ehninger G, Schuler HK, Sarnow E (1996) Fluconazole in the prophylaxis of fungal infection after bone marrow transplantation. Mycoses 39(7–8):259–263
53. Ahmad I, Wahid Z, Nasreen S, Ansari F (2004) Fluconazole pulse therapy: effect on inflammatory tinea capitis (kerion and agminate folliculitis). J Pak Assoc Dermatol. 14:70–74
54. Güpüncan AN, Balkan E, Kiliç N, Kirişçölü I, Avşar I, Doğruyol H (1997) Fluconazole treatment of neonates and infants with severe fungal infections. J Int Med Res 25:214–218
55. Marchiso P, Principi N (1994) Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Eur J Clin Microbiol Infect Dis 13:694
56. Prestrel E, Grüninger W, Bammer KW, Dopfer R, Schmitz HJ, Gadner H et al (1994) Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Eur J Clin Microbiol Infect Dis 13:347–351
57. Fasano C, O’Keeffe J, Gibbs D (1994) Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 13:351–354
58. Diessens M, Ellis JB, Muwazi F, De Villiers FPR (1997) The treatment of systemic candidiasis in neonates with oral fluconazole. Ann Trop Paediatr 17:263–271
59. Bilgen H, Özek E, Korten V, Ener B, Molbay D (1995) Treatment of systemic neonatal candidiasis with fluconazole [1]. Infection 23:347
60. Kamiya H, Ibara T, Yasuda N, Sakurai M, Ito M, Azuma E et al (1994) Experience of fluconazole granules and injection in pediatric patients. Jpn J Antibiot 47:280–288
61. Krzeska L, Yeates RA, Pfaff G (1993) Single dose intravenous fluconazole prophylaxis in children. J Perinatol 13:631–637
62. Driessen M, Ellis JB, Muwazi F, De Villiers FPR (1997) The treatment of systemic candidiasis in neonates with oral fluconazole. Ann Trop Paediatr 17:263–271
63. Bilgen H, Özek E, Korten V, Ener B, Molbay D (1995) Treatment of systemic neonatal candidiasis with fluconazole [1]. Infection 23:347
64. Kamiya H, Ibara T, Yasuda N, Sakurai M, Ito M, Azuma E et al (1994) Experience of fluconazole granules and injection in pediatric patients. Jpn J Antibiot 47:280–288
65. Sugita K, Miyake M, Takitani K, Murata T, Nishimura T, Aoki S (1994) Pharmacokinetic and clinical evaluations of fluconazole in pediatric patients. Jpn J Antibiot 47:296–303
66. Groll A, Nowak-Gottl U, Wildfeuer A, Weise M, Schwabe D, Gerein V et al (1994) Fluconazole prophylaxis of oropharyngeal candidiasis in pediatric cancer patients with severe mucositis following antineoplastic chemotherapy. Mycoses 35(Suppl):35–40
67. Godula-Stügluk U (1997) Endotracheal colonisation with Candida albicans in prolonged ventilated neonates—clinical manifestations and treatment with oral fluconazole. Pediatr Relat Top 35:459–465
68. Caballero S, Jaraba Caballero MP, Fernández Gutiérrez F, Muriel Zafra I, Huertas Muñoz MD, Álvarez Marcos R et al (1998) Prospective study of Candida sepsis in the neonate. Estudio prospectivo de sepsis por Candida en el recien nacido 48:639–643
69. Saporito N, Tina LG, Betta P, Sciaccia A (1994) Fluconazole in the treatment of Candida albicans infection in premature infants. Clin Pediatr Chir 16:263–267
70. Byers M, Chapman S, Feldman S, Parent A (1992) Fluconazole pharmacokinetics in the cerebrospinal fluid of a child with Candida tropicalis meningitis. Pediatr Infect Dis J 11:895–896
71. Krzeska L, Yeates RA, Pfaff G (1993) Single dose intravenous pharmacokinetics of fluconazole infants. Drugs Exp Clin Res 19:267–271
72. Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh TJ (1992) Safety and pharmacokinetics of fluconazole in children with neoplastic disease. Pharmacotherapy 15:52
73. Uden DL (1995) Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic disease. Pharmacotherapy 15:52–58
Supplementary references

81. Ahirara Y, Mori M, Yokota S (1996) Successful treatment of onychomycosis with fluconazole in two patients with hyperimmunoglobulin E syndrome. Pediatr Dermatol 13:493–495
82. Assaf RR, Elewski BE (1996) Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol 35(2 Part 1):216–219
83. Bode S, Pedersen-Bjergaard L, Hjelt K (1992) Candida albicans septicemia in a premature infant successfully treated with oral fluconazole. Scand J Infect Dis 24:673–675
84. Bergman KA, Meis JF, Horrevorts AM, Monnens L (1992) Acute renal failure in a neonate due to pelviureteric candidal bezoars successfully treated with long-term systemic fluconazole. Acta Paediatr Int J Paediatr 81(9):709–711
85. Bunin N (1989) Oral fluconazole for treatment of disseminated fungal infection. Pediatr Infect Dis J 8(1):62
86. Bonnet E, Massip P, Bauriadal LA, Auvergnat J (1996) Fluconazole monotherapy for Candida meningitis in premature infant. Clin Infect Dis 23:645–646
87. Cap J, Seijnova V, Soltes L, Krcmery V Jr (1991) Fluconazole in the treatment of mycotic infection in children. Int J Exp Clin Chemother 4(4):219–223
88. Cruciani M, Di Perri G, Molemsi M, Vento S, Concia E, Bassetti D (1992) Use of fluconazole in the treatment of Candida albicans hydrocephalus shunt infection. Eur J Clin Microbiol Infect Dis 11(10):957
89. Guillén Fiel G, Gonzalez-Granado LI, Mosqueda R, Negreina S, Giangaspro E (2009) Arthritis caused by Candida in an immunocompetent infant with a history of systemic candidiasis in the neonatal period. Ann Pediatr (Paris) 70(4):383–385
90. Filipowicz J, Kozlowski M, Iga N, Szalewska M, Zurovska A, Slusarczyk M (1997) Acute renal insufficiency during Candida albicans candidiasis in a 2-month-old infant (in Polish). Przegl Lek 54(1):73–75
91. Hsieh WB, Leung C (2005) Candidal arthritis after complete treatment of systemic candidiasis. J Clin Med Assoc 68:191–194
92. Kamitsuka M, Nugent NA, Conrad PD, Swanston TN (1995) Candida albicans brain abscesses in a premature infant treated with amphotericin B, flucytosine and fluconazole. Pediatr Infect Dis J 14(4):329–331
93. Kawamori J, Tsuruta S, Yoshida T (1997) Effect of fluconazole on Aspergillus infection associated with chronic granulomatous disease (in Japanese). Kansenshogaku zasshi (J Jpn Assoc Infect Dis) 65(9):1200–1204
94. Maruta A, Matsuzaki M, Fukawa H, Kodama F (1989) Clinical evaluation of fluconazole in the case of deep mycosis associated with leukemia. Jpn J Antimicrob Chemother 42(1):117–126
95. Zia-ul-Miraj M, Mirza I (1997) Fluconazole for treatment of fungal infections of the urinary tract in children. Pediatr Surg Int 12(5–6):414–416
96. Mercurio MG, Silverman RA, Elewski BE (1998) Tinea capitis: fluconazole in Trichophyton tonsurans infection. Pediatr Dermatol 15(3):229–232
97. Morris SA, Bailey CJ, Cartledge JM (1994) Neonatal renal candidiasis. J Paediatr Child Health 30(2):186–188
98. Oka S, Tokitsu M, Mori H, Nakata H, Goto M, Shimida K (1989) Clinical evaluation of fluconazole. Jpn J Antimicrob Chemother 42(1):31–39
99. Olenik EM, Della-Latta P, Rinaldi MG, Saiman L (1993) Candida lusitaniae osteomyelitis in a premature infant. Am J Perinatol 10(4):313–315
100. Neal DE Jr, Rodríguez G, Hanson JA, Harmon E (1996) Fluconazole treatment of fungal UTIs in pediatric patients. Infect Med 13(3):169–70+77
101. Aguilar Olmos R, Mezquita Edo C, Escorihuela Centelles A, Moreno Palanques MA, Rosales Marza A, Alos Alminana M, et al (1995) Systemic neonatal candidiasis. Treatment with fluconazole (in Spanish). Rev Esp Pediatr 54(1):572–574
102. Perrica JM, Dayecka N, Hui CPS (2009) Rectal fluconazole for tinea capitis. Paediatr Child Health 14:573–574
103. Ratajczak B, Wierzbka J, Irga N, Czarnik P, Kosiak W, Samet A, et al (1996) The clinical course of fungal urinary tract infection in neonates (in Polish). Ped Pol 71:331–337
104. Ramdas K, Minamoto GY (1994) Candidal sepsis and meningitis. J Paediatr Child Health 30(2):186–188
105. Oka S, Tokitsu M, Mori H, Nakata H, Goto M, Shimida K (1989) Clinical evaluation of fluconazole. Jpn J Antimicrob Chemother 42(1):31–39
106. Olenik EM, Della-Latta P, Rinaldi MG, Saiman L (1993) Candida lusitaniae osteomyelitis in a premature infant. Am J Perinatol 10(4):313–315
107. Neal DE Jr, Rodríguez G, Hanson JA, Harmon E (1996) Fluconazole treatment of fungal UTIs in pediatric patients. Infect Med 13(3):169–70+77
108. Aguilera Olmos R, Mezquita Edo C, Escorihuela Centelles A, Moreno Palanques MA, Rosales Marza A, Alos Alminana M, et al (1995) Systemic neonatal candidiasis. Treatment with fluconazole (in Spanish). Rev Esp Pediatr 54(1):572–574
109. Perrica JM, Dayena N, Hui CPS (2009) Rectal fluconazole for tinea capitis. Paediatr Child Health 14:573–574
110. Ratajczak B, Wierzbka J, Irga N, Czarnik P, Kosiak W, Samet A, et al (1996) The clinical course of fungal urinary tract infection in neonates (in Polish). Ped Pol 71:331–337
111. Ramdas K, Minamoto GY (1994) Candidal sepsis and meningitis. J Paediatr Child Health 30(2):186–188
112. Oka S, Tokitsu M, Mori H, Nakata H, Goto M, Shimida K (1989) Clinical evaluation of fluconazole. Jpn J Antimicrob Chemother 42(1):31–39
113. Olenik EM, Della-Latta P, Rinaldi MG, Saiman L (1993) Candida lusitaniae osteomyelitis in a premature infant. Am J Perinatol 10(4):313–315
114. Neal DE Jr, Rodríguez G, Hanson JA, Harmon E (1996) Fluconazole treatment of fungal UTIs in pediatric patients. Infect Med 13(3):169–70+77
115. Aguilera Olmos R, Mezquita Edo C, Escorihuela Centelles A, Moreno Palanques MA, Rosales Marza A, Alos Alminana M, et al (1995) Systemic neonatal candidiasis. Treatment with fluconazole (in Spanish). Rev Esp Pediatr 54(1):572–574
116. Perrica JM, Dayecka N, Hui CPS (2009) Rectal fluconazole for tinea capitis. Paediatr Child Health 14:573–574
117. Ratajczak B, Wierzbka J, Irga N, Czarnik P, Kosiak W, Samet A, et al (1996) The clinical course of fungal urinary tract infection in neonates (in Polish). Ped Pol 71:331–337
118. Ramdas K, Minamoto GY (1994) Candidal sepsis and meningitis in a very-low-birth weight infant successfully treated with fluconazole and flucytosine. Clin Infect Dis 19:795–796
119. Stocker M, Caduff JH, Spalinger J, Berger TM (2000) Successful treatment of bilateral renal fungal balls with liposomal amphotericin B and fluconazole in an extremely low birth weight infant. Eur J Pediatr 159(9):676–678
120. Tucker RM, Galgiani JN, Denning DW, Hanson LH, Graybill JR, Sharkey K et al (1990) Treatment of coccidiodial meningitis with fluconazole. Rev Infect Dis 12[Suppl 3]:S380–S389
121. Van’t Wout JW, De Graeff-Meeder ER, Paul LC, Kuis W, Van Furth R (1988) Treatment of two cases of cryptococcal meningitis with fluconazole. Scand J Infect Dis 20(2):193–198
108. Viscoli C, Castagnola E, Corsini M, Gastaldi R, Soliani M, Terragna A (1989) Fluconazole therapy in an underweight infant. Eur J Clin Microbiol Infect Dis 8(10):925–926

109. Wakiguchi H, Hisakawa H, Sinohara M, Watanabe S, Okada T, Misaki Y et al (1994) Fluconazole therapy for pediatric patients with severe candidal infections. Jpn J Antibiot 47(3):304–308

110. Weintrub PS, Chapman A, Piecuch R (1994) Renal fungus ball in a premature infant successfully treated with fluconazole. Pediatr Infect Dis J 13(12):1152–1154

111. Yagi S, Watanabe M, Nakajima M, Tsukiyama K, Moriya O, Hino J et al (1989) A clinical evaluation of fluconazole in the treatment of deep mycosis. Jpn J Antibiot 42(1):144–152